Inhibition of COX-2 prevents hypertension and proteinuria associated with a decrease of 8-iso-PGF2α formation in L-NAME-treated rats

Journal of Hypertension

Volumn 21, Issue 3, 2003, Pages 601-609

  Tomida, Takahito ^a   Numaguchi, Yasushi ^a   Nishimoto, Yasuhiro ^a   Tsuzuki, Michitaka ^a   Hayashi, Yuzo ^a   Imai, Hajime ^a   Matsui, Hideo ^a   Okumura, Kenji ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

8 iso prostaglandin F2 ; Cyclooxygenase; Kidney; Nitric oxide; Thoracic aorta

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ARACHIDONIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROSTAGLANDIN E2; THROMBOXANE A2 RECEPTOR; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CYTOKINE RELEASE; HEART RATE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTAGLANDIN URINE LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; URINE VOLUME;

EID: 0037358022     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200303000-00027     Document Type: Article

References (29)

1. Qui C, Muchant D, Beierwaltes WH, Racusen L, Baylis C. Evolution of chronic nitric oxide inhibition hypertension. Relationship to renal function. Hypertension 1998; 31:21-26.
2. Ono H, Ono Y, Frohlich ED. ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats. Hypertension 1996; 27:176-183.
3. Usui M, Egashira K, Kitamoto S, Koyanagi M, Katoh M, Kataoka C, et al. Pathogenic role of oxidative stress in vascular angintensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. Hypertension 1999; 34:546-551.
4. Tomita H, Egashira K, Kubo-Inoue M, Usui M, Koyanagi M, Shimokawa H, et al. Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol 1998; 18:1456-1464.
5. Davidge ST, Baker PN, McLaughlin MK, Roberts JM. Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase. Circ Res 1995; 77:274-283.
6. Pomposiello S, Yang XP, Liu YH, Surakanti M, Rhaleb N-E, Sevilla M, et al. Autacoids mediate coronary vasoconstriction induced by nitric oxide synthesis inhibition. J Cardiovasc Pharmacol 1997; 30:599-606.
7. Ziyyat A, Zhang BL, Benzoni D. Interactions between nitric oxide and prostanoids in isolated perfused kidneys of the rat. Er J Pharmacol 1996; 119:388-392.
8. Ohnaka K, Numaguchi K, Yamakawa T, Inagami T. Induction of cyclooxygenase-2 by Ang II in cultured rat vascular smooth muscle cells. Hypertension 2000; 35:68-75.
9. Young W, Mahboubi K, Haider A, Li I, Ferreri NR. Cyclooxygenase-2 is required for tumor necrosis factor-α and angiotensin II-mediated proliferation of vascular smooth muscle cells. Circ Res 2000; 86:906-914.
10. Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 1999; 274:5038-5046.
11. LaPointe MC, Isenovic E. Interleukin-1β regulation of inducible nitrio oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes. Hypertension 1999; 33:276-282.
12. Vio CP, Cespedes C, Gallardo P, Masferrer JL. Renal indentification of cyclooxygenase-2 in a subset of the ascending limb cells. Hypertension 1997; 30:687-692.
13. Hartner A, Goppelt-Struebe M, Hingers KF. Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension. Hypertension 1998; 31:201-205.
14. Wang JL, Cheng HF, Harris RO. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 1999; 34:96-101.
15. Wolf K, Castrop H, Hartner A, Goppelt-Strübe M, Hilgers, Kurtz A. Inhibition of the renin-angiotensin system upregulates cyclooxygenase-2 expression in the macula densa. Hypertension 1999; 37:503-507.
16. Sundaram P. A simplified 'coupled' probing approach for the detection of proteins on dot and western blots. J Immunol Methods 1996; 195:149-152.
17. Pistello M, Menzo S, Giorge M, Da Prato L, Cammarota G, Clementi M, et al. Competitive polymerase chain reaction for quantitating feline immunodeficiency virus load in infected cat tissues. Mol Cell Probes 1994; 8:229-234.
18. Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension 1993; 21:660-666.
19. Feng L, Xia Y, Garcia GE, Hwang D, Wilson CB. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-α and lipopolysaccharide. J Clin Invest 1995; 95:1669-1675.
20. Cowley AW Jr, Mattson DL, Lu S, Roman RJ. The renal medulla and hypertension. Hypertension 1995; 25:663-673.
21. Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol 2001; 281:F1-F11.
22. Rokach J, Khanapure SP, Hwang SW, Adiyaman M, Lawson JA, Fitzgerald GA. The isoprostanes: a perspective. Prostaglandins 1997; 54:823-851.
23. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Atheroscler Thromb Vasc Biol 1997; 17:2309-2315.
24. 2α during cyclooxygenase inhibition in rats but not in man. Br J Pharmacol 1997; 121:1770-1774.
25. Patrignani P, Santini G, Panara MR, Sciulli MG, Greco A, Rotondo MT, et al. Induction of prostaglandin endoperoxide synthase-2 in human monocytes associated with cyclo-oxygenase-dependent F2-isoprostane formation. Br J Pharmacol 1996; 118:1285-1293.
26. Fukunaga M, Makita N, Roberts II LJ, Morrow JD, Takahashi K, Badr KF. Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. Am J Physiol 1993; 264:C1619-C1624.
27. 2 receptors. J Clin Invest 1992; 90:136-141.
28. Brater DC. Renal effects of cyclooxygenase-2-selective inhibitors. J Pain Symptom Manage 2002; 23:S15-20.
29. 2α, in humans. J Mass Spectrom 1997; 32:1362-1370.